200 BERKELEY STREET, BOSTON, MA
Reports First Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio Enters Exchange Agreement for 250,000 Shares with RA Capital
Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Provides Corporate Update and Highlights Expected 2026 Milestones
Amendments to Articles of Incorporation or Bylaws, Other Events
Adicet Bio, Inc. Stockholders Approve Reverse Stock Split Proposal
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Amended Annual Report
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
S-8 POS
Correspondence
Submission Upload
Definitive Revised Proxy Statement